USPTO 2015–2025 USPTO PatentsView Foreign Corporation

TheVax Genetics Vaccine Co., Ltd.

USPTO PatentsView assignee record - 6 granted patents across 6 technology areas, recorded in grant years 2016–2018. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Thevax ranks #43,645 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 6 technology areas.

#43,645
of 49,997 US assignees by volume
21st percentile
by Innovation Score (26.8/100)
19.0
avg claims per patent
-100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R43645 · Foreign Corporation #43,645 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 6 grants
  • LOWER-Q #43,645/49,997
  • PHOTO-FINISH The Western…
  • CPC-NARROW A61P · 6 areas
  • INNOV-THIN 26.8/100
  • CLAIMS-RICH 19.0 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DROP -100% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: The Western Australian Agriculture Authority (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Thevax

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Thevax's Innovation Score is 26.8/100 (21st percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Thevax's grants concentrate

TheVax Genetics Vaccine Co., Ltd. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (3 grants) versus a trough of 1 in 2018. By volume, Thevax sits between The Western Australian Agriculture Authority and Think-Cell Software GMBH.

Who files at TheVax's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows TheVax holds 6 patents at rank #43,679, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near TheVax

By rank, the assignees closest to #43,679 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in TheVax's primary technology class.

Thevax's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 21st percentile higher than 21% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 201620172018 1
USPTO utility patent grants by year · 2016–2018

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
TheVax Genetics Vaccine Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 2 33.3%
2017 3 50.0%
2018 1 16.7%

Where it ranks

Overall rank by patents

#43,645

of 49,997 tracked assignees

Innovation Score

26.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

TheVax Genetics Vaccine Co., Ltd.'s patent record in context - here's where to go next.

  • TheVax Genetics Vaccine Co., Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #43,645 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare TheVax Genetics Vaccine Co., Ltd. against The Western Australian Agriculture Authority, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 26.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.